On January 15, 2026, Yaohai Bio-Pharma’s strategic partner, Wuhan Huajiyuan Biotechnology Development Co., Ltd. (Huajiyuan Biotech), announced that its independently developed product, HJY-ATRQβ-001, the world’s first therapeutic hypertension vaccine, is expected to be officially launched in China in 2029.
HJY-ATRQβ-001 Injection received clinical trial approval from the National Medical Products Administration (NMPA) of China in August 2024 and has since entered preparations for Phase I clinical trials. According to the development plan, Wuhan Huajiyuan Biotec aims to complete Phase I, Phase IIa, and Phase IIb studies within three years, followed by submission of an application for conditional marketing authorization to the Center for Drug Evaluation (CDE).
As a key CDMO partner for the HJY-ATRQβ-001 project, Yaohai Bio-Pharma extends its warm congratulations to Wuhan Huajiyuan Biotec on this important milestone.
Yaohai Bio-Pharma’s Contribution
During this collaboration, Yaohai Bio-Pharma provided one-stop, full-lifecycle CMC development and regulatory submission services for the HJY-ATRQβ-001 project. By leveraging strong technical capabilities, extensive project experience, and efficient regulatory execution, Yaohai worked closely with the Wuhan Huajiyuan Biotec team to support the smooth approval of the clinical trial application.
Notably, the project passed the formal review process with zero supplemental documentation requests, and no deficiencies were raised during the technical evaluation stage. As a result, the clinical approval timeline was significantly shortened, accelerating the clinical translation of this first-in-class innovation.
About HJY-ATRQβ-001
HJY-ATRQβ-001 is an injectable therapeutic hypertension vaccine based on a first-in-class biased signaling mechanism. It selectively regulates G protein–coupled receptor and β-arrestin2 signaling pathways, enabling precise intervention in the pathological mechanisms of hypertension.
In addition, by modulating both axes of the renin–angiotensin system (RAS), the vaccine demonstrates not only effective blood pressure reduction but also meaningful target organ protection. Preclinical data suggest benefits such as delayed progression of diabetic nephropathy and inhibition of atherosclerosis.
The regulatory approval of HJY-ATRQβ-001 represents a landmark breakthrough in hypertension treatment innovation in China. It offers a promising long-acting, safe, and convenient therapeutic option for an estimated 1.4 billion patients with hypertension in the world.
About Huajiyuan Biotech
Wuhan Huajiyuan Biotechnology Development Co., Ltd. was founded in June 2013 by Professor Liao Yuhua from the Department of Cardiology at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The company is located in Optics Valley BioCity and focuses on the development of ultra-long-acting therapeutic vaccines for cardiovascular diseases.
Its pipeline includes therapeutic vaccines for hypertension, hyperlipidemia, diabetes, and pulmonary arterial hypertension. All programs have completed preclinical proof-of-concept studies, with 10 invention patents granted. Research on the ATRQβ-001 therapeutic hypertension vaccine has received national support since 2009 and was included in China’s National Major New Drug Innovation Program in 2014.
About Yaohai Bio-Pharma
Yaohai Bio-Pharma is a CRDMO with extensive expertise in microbial expression systems. We focus on recombinant proteins, nucleic acid drugs, nanobodies, plasmid DNA, and innovative vaccines. From R&D to commercial manufacturing, we offer full-lifecycle solutions. Our mission is to build an open, integrated CRO/CDMO/MAH platform that supports global partners from discovery to market.
